Systemic and topical retinoids in the management of skin cancer in organ transplant recipients
Systemic and topical retinoids in the management of skin cancer in organ transplant recipients
复制标题
DOI：
10.1111/j.1524-4725.2004.30152.x
复制
发表时间：
2004-04-01
影响因子：
2.4
通讯作者：
Bavinck, JNB
中科院分区：
文献类型：
--
作者：
De Graaf, YGL;Euvrard, S;Bavinck, JNB
背景。非黑色素瘤皮肤癌是器官移植患者中最常见的恶性肿瘤。发生多种新发皮肤癌的患者可能受益于类维甲酸化学预防。本研究的目的是为器官移植受者使用类维生素a提供建议。本文对器官移植患者使用类维生素A化学预防皮肤癌的相关文献进行了总结。系统性类维生素a，特别是阿维a素，在器官移植患者中有效抑制肿瘤发展。然而，这种效果只在治疗期间出现。局部类维甲酸治疗光化性角化病有一定效果。结论和建议。全身类维生素a可用于皮肤癌的化学预防。为了获得良好的效果，长期服用阿维素是必要的。然而，副作用限制了类维甲酸化学预防的使用。建议以低剂量开始治疗，并应定期监测患者的甘油三酯和胆固醇水平以及转氨酶。
BACKGROUND. Nonmelanoma skin cancers are the most frequent malignancies in organ transplant patients. Patients who develop multiple new skin cancers may benefit from retinoid chemoprevention.OBJECTIVE. The objective of this study was to advise on the use of retinoids in organ transplant recipients.METHODS. A summary was performed of the existing literature regarding experience with retinoid chemoprevention for skin cancer in organ transplant patients.RESULTS. Systemic retinoids, specifically acitretin, are effective in inhibiting tumor development in organ transplant patients. This effect is only present during therapy, however. Topical retinoids have some effect in the treatment of actinic keratoses.CONCLUSIONS AND RECOMMENDATIONS. Systemic retinoids can be used for chemoprevention of skin cancer. For a good result, long-term treatment with acitretin is necessary. Side effects, however, limit the use of retinoid chemoprevention. It is advised that treatment be started at a low dose, and patients should be monitored regularly for triglyceride and cholesterol levels and transaminases.